Services

Strategic Scientific & Quality Advisory for Life Sciences Organizations

I work with life sciences companies at critical inflection points — where scientific ambition, quality expectations, and business decisions intersect. My role is to provide an independent, senior-level perspective that helps leadership teams and boards make confident, defensible decisions in complex and regulated environments.

Drawing on over 30 years of global experience — including formative work in Japan, where quality management principles are deeply embedded in organizational culture — I help organizations move beyond compliance and build a mature, practical understanding of Quality Management Systems (QMS) as a leadership and decision-making framework.

How I Support Organizations

1. Board & Executive Advisory

I advise boards, founders, and executive teams on scientific, quality, and translational strategy at moments when judgment matters more than execution.

Typical focus areas:

• Scientific and quality governance

• Risk awareness at the board level

• Strategic readiness for growth, partnerships, or investment

• Independent perspective on critical decisions
  
  

Format: advisory meetings, board sessions, executive discussions (virtual or in person)

2. Quality Systems as a Strategic Enabler

Many organizations approach QMS primarily as a compliance requirement. I help leadership teams reframe quality as a strategic system that supports credibility, scalability, and long-term value.

What this looks like in practice:

• Deep discussions of core QMS principles using real organizational cases

• Clarifying common misconceptions (e.g. leadership as a system-wide responsibility, not only

 a management function)

• Aligning quality systems with scientific strategy and organizational maturity
  
  

The goal is not documentation — it is shared understanding and better decisions.

3. Scientific, Preclinical & Translational Risk Advisory

I support leadership teams in identifying and addressing scientific and translational risks before they become regulatory, financial, or reputational liabilities.

Support includes:

• Strategic review of preclinical and translational assumptions

• Readiness assessments for the next development or funding stages

• Framing scientific complexity in decision-ready language for executives and investors
  
  

4. Strategic Reviews & Decision Support

For organizations facing high-stakes choices, I provide focused, time-bound strategic input.

Examples:

• Scientific or quality readiness reviews

• Portfolio or program decision support

• Investor or partner-facing risk clarification

These engagements are designed to bring clarity, not create additional operational burden.

How I Work

• Senior, independent, and objective

• Advisory, not operational execution

• Focused on judgment, clarity, and long-term impact

• Flexible formats: ad-hoc advisory, retainers, board or committee roles
  
  

I am most effective when engaged early enough to influence direction — not after problems have already materialized.

Who I Work With

• Life sciences and biotech companies

• Diagnostics and regulated technology organizations

• Investors and boards seeking scientific and quality insight

• Early- and growth-stage companies navigating complexity and scale
  
  

Let’s Talk

If your organization is navigating growth, innovation, regulatory expectations, or strategic uncertainty, I welcome a conversation to explore whether my perspective would be valuable.

For advisory or board-related inquiries, you may contact me at anelia.atanassova@bioglobax.com